This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Utomilumab
DrugBank Accession Number
DB15113
Background

Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

Type
Biotech
Groups
Investigational
Synonyms
  • PF-05082566
  • Utomilumab

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Utomilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Utomilumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Utomilumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Utomilumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Utomilumab.
AmivantamabThe risk or severity of adverse effects can be increased when Utomilumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Utomilumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Utomilumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Utomilumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Utomilumab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
6YY8O697VF
CAS number
1417318-27-4

References

General References
Not Available
Wikipedia
CD137

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentAdvanced Malignancies / Non-Small Cell Lung Carcinoma (NSCLC) / Ovarian Cancer / Solid Tumors / Urothelial Cancer1
3TerminatedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2CompletedTreatmentMalignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Oropharyngeal Cancers1
2RecruitingTreatmentBreast Cancer1
2RecruitingTreatmentBreast Cancer Stage IIIc / Breast Cancer, Stage III / Breast Cancer, Stage IIIB / Carcinoma Breast Stage IV / Invasive Breast Carcinoma / Recurrent Breast Carcinoma / Stage IIIA Breast Cancer / Triple Negative Breast Carcinoma / Unresectable Breast Carcinoma1
1Active Not RecruitingTreatmentCOL6A3 Positive / HLA-A*0201 Positive Cells Present / PRAME Positive / Recurrent Ovarian Carcinoma1
1Active Not RecruitingTreatmentFollicular Lymphoma ( FL)1
1Active Not RecruitingTreatmentMetastatic Colorectal Carcinoma / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v81
1Active Not RecruitingTreatmentRecurrent Diffuse Large B-Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Diffuse Large B Cell Lymphoma (DLBCL) / Refractory Mantle Cell Lymphoma / Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma1
1Active Not RecruitingTreatmentRelapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 14:50 / Updated at February 21, 2021 18:55